GSK PLC (GSK)
39.74
+0.48
(+1.21%)
USD |
NYSE |
Apr 19, 16:00
39.76
+0.02
(+0.04%)
After-Hours: 17:38
GSK SG&A Expense (Quarterly): 3.326B for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 3.326B |
September 30, 2023 | 2.907B |
June 30, 2023 | 2.839B |
March 31, 2023 | 2.605B |
December 31, 2022 | 2.867B |
September 30, 2022 | 2.420B |
June 30, 2022 | 2.597B |
March 31, 2022 | 2.431B |
December 31, 2021 | 2.956B |
September 30, 2021 | 2.315B |
June 30, 2021 | 2.361B |
March 31, 2021 | 3.346B |
December 31, 2020 | -1.131B |
September 30, 2020 | 3.449B |
June 30, 2020 | 3.359B |
March 31, 2020 | 3.738B |
December 31, 2019 | 4.435B |
September 30, 2019 | 3.563B |
June 30, 2019 | 3.329B |
March 31, 2019 | 3.227B |
December 31, 2018 | 3.371B |
September 30, 2018 | 3.292B |
June 30, 2018 | 3.348B |
March 31, 2018 | 3.213B |
December 31, 2017 | 3.364B |
Date | Value |
---|---|
September 30, 2017 | 3.021B |
June 30, 2017 | 3.041B |
March 31, 2017 | 3.037B |
December 31, 2016 | 3.368B |
September 30, 2016 | 3.011B |
June 30, 2016 | 3.123B |
March 31, 2016 | 3.134B |
December 31, 2015 | 3.789B |
September 30, 2015 | 3.050B |
June 30, 2015 | 3.892B |
March 31, 2015 | 3.373B |
December 31, 2014 | 3.491B |
September 30, 2014 | 3.361B |
June 30, 2014 | 3.458B |
March 31, 2014 | 3.261B |
December 31, 2013 | 3.561B |
September 30, 2013 | 3.076B |
June 30, 2013 | 3.404B |
March 31, 2013 | 3.231B |
December 31, 2012 | 3.549B |
September 30, 2012 | 3.531B |
June 30, 2012 | 3.483B |
March 31, 2012 | 3.365B |
December 31, 2011 | 3.413B |
September 30, 2011 | 3.241B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
-1.131B
Minimum
Dec 2020
4.435B
Maximum
Dec 2019
2.827B
Average
2.907B
Median
Sep 2023
SG&A Expense (Quarterly) Benchmarks
AstraZeneca PLC | 3.983B |
Haleon PLC | 1.357B |
Novo Nordisk A/S | 2.688B |
Pfizer Inc | 4.575B |
Sanofi SA | 3.156B |